Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Agents for Skin Inflammation After 5-FU for Actinic Keratosis
NCT03279328Phase 4Completed
- Sponsor
- University of Arizona
- Start
- Oct 2017
- Primary completion
- Jul 2018
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 1
01
Overview
A Phase 4 trial of surabgene lomparvovec in actinic keratosis (AK), sponsored by University of Arizona. Started Oct 2017; status: completed.
02
Drugs
surabgene lomparvovec
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NCT03279328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03279328.